Premium
Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21
Author(s) -
Scandurra Marta,
Mian Michael,
Greiner Timothy C.,
Rancoita Paola M. V.,
De Campos Cassio P.,
Chan Wing C.,
Vose Julie M.,
Chigrinova Ekaterina,
Inghirami Giorgio,
Chiappella Annalisa,
Baldini Luca,
Ponzoni Maurilio,
Ferreri Andres J.M.,
Franceschetti Silvia,
Gaidano Gianluca,
MontesMoreno Santiago,
Piris Miguel A.,
Facchetti Fabio,
Tucci Alessandra,
Nomdedeu Josep Fr.,
Lazure Thierry,
Lambotte Olivier,
Uccella Silvia,
Pinotti Graziella,
Pruneri Giancarlo,
Martinelli Giovanni,
Young Ken H.,
Tibiletti Maria Grazia,
Rinaldi Andrea,
Zucca Emanuele,
Kwee Ivo,
Bertoni Francesco
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08326.x
Subject(s) - vincristine , diffuse large b cell lymphoma , chop , lymphoma , oncology , medicine , cyclophosphamide , rituximab , prednisone , population , biology , chemotherapy , environmental health
Summary Despite recent therapeutic improvements, the clinical course of diffuse large B‐cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi‐centre study to evaluate the impact of genomic aberrations detected using a high‐density genome wide‐single nucleotide polymorphism‐based array on clinical outcome in a population of DLBCL patients treated with R‐CHOP‐21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R‐CHOP‐21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p‐ and 15q‐. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R‐CHOP, have been identified by arrayCGH.